tiprankstipranks
TipRanksTop Financial ExpertsInsidersMartin Mackay

Martin Mackay Insider Profile

4 Followers
Martin Mackay, EVP & Global Head of R&D at Alexion Pharmaceuticals, holds 17.14K shares in Charles River Labs (Ticker: CRL), holds 0.00 shares in Springworks Therapeutics (Ticker: SWTX), holds 719.13K shares in Rallybio (Ticker: RLYB).
See the Hottest Stocks Based on Insider Trading >
tipranks
Martin Mackay

Martin Mackay
Alexion Pharmaceuticals (ALXN)
EVP & Global Head of R&D

Ranked #14,599 out of 107,360 Corporate Insiders

Profitable Transactions

79%
11 out of 14 Profitable Transactions

Average Return

+9.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
How are Insiders Ranked?

Insider Holdings

$24M
47.10%
41.57%
11.33%
0.00%
A breakdown of Martin Mackay's holdings
See the Top Stocks by Insiders

Insider Roles

Rallybio
(RLYB)
Director
Pfizer
(PFE)
SVP
Charles River Labs
(CRL)
Director
Kailera Therapeutics, Inc.
(KLRA)
Director
Roles that Martin Mackay holds in companies
See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:
Alexion Pharmaceuticals
(ALXN)
Rating:Informative Sell
Date:Aug 05, 2015 - Aug 05, 2016
Return:+30.70%
The most profitable trade made by Martin Mackay
See the Latest Stocks Traded by Insiders

Martin Mackay's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
ALXN
Alexion Pharmaceuticals
Mar 01, 2017
―
Uninformative Buy
―
$7.44M
CRL
Charles River Labs
May 11, 2026
Director
Uninformative Buy
505.33K
$2.75M
FVAM
5:01 Acquisition Corp Class A
―
―
―
―
RLYB
Rallybio
Jan 12, 2022
Director
Uninformative Buy
―
$11.42M
SWTX
Springworks Therapeutics
Jul 02, 2025
―
Uninformative Sell
―
$0.00
KLRA
Kailera Therapeutics, Inc.
―
Director
―
―
PFE
Pfizer
Mar 01, 2010
SVP
Uninformative Buy
―
$10.08M
List of latest transactions for each holding click on a transaction to see Martin Mackay's performance on stock
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Martin Mackay insider profile FAQ

What is the percentage of profitable transactions made by Martin Mackay?
The percentage of profitable transactions made by Martin Mackay is 79%.
    What is the average return per transaction made by Martin Mackay?
    The average return per transaction made by Martin Mackay is 9.50%.
      What stocks does Martin Mackay hold?
      Martin Mackay holds: ALXN, CRL, FVAM, RLYB, SWTX, KLRA, PFE stocks.
        What was Martin Mackay’s latest transaction?
        Martin Mackay latest transaction was an Uninformative Buy of $505.33K.
          What was Martin Mackay's most profitable transaction?
          Martin Mackay’s most profitable transaction was an Informative Sell of ALXN stock on August 5, 2015. The return on the trade was 30.70%.
            What is Martin Mackay's role in Alexion Pharmaceuticals?
            Martin Mackay's role in Alexion Pharmaceuticals is EVP & Global Head of R&D.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.